The effect of a fat-and liquid-calcium-rich meal on the pharmacokinetics of single and multiple doses of fleroxacin in 20 healthy men and women was investigated in a randomized crossover fashion. Fleroxacin was administered as 400 mg daily for 3 days and as a single 400 mg dose. Concurrent administration of fleroxacin with food resulted in a statistically significant (P c 0.05) decrease in the area under the curve (13.9%Yo for multiple-dose administration, 10% for single-dose administration) and in the peak concentration (25.9% for multiple-dose administration, 27% for single-dose administration) and a lengthening of the time to peak (more than doubled for single-and multiple-dose phases). In addition, by using an equivalence criteria of 80 to 125%, the two one-sided tests procedure indicated that the mean areas under the curves for fleroxacin administered in a fed and a fasted state were statistically bioequivalent (P ' 0.05) for both the single-and multiple-dose regimens. Although a meal high in fat and containing liquid calcium reduces the peak concentration by approximately 25%, a minimal eflect on bioavailability is seen with concomitant food administration. In addition, multiple-dose bioavailability studies appear to give similar information to single-dose studies while representing the clinical setting more closely.
distribution (Vss) ranges from 1.2 to 1.7 liters/kg, and total body clearance (CL) ranges from 5.9 to 10.6 liters/h (6, 14) . The drug is approximately 23% protein bound. The oral absorption of fleroxacin is characterized by nearly complete bioavailability. From 45 to 70% of the drug is renally excreted as unchanged fleroxacin.
The interaction of fluoroquinolones with food has been studied extensively. Results of pharmacokinetic studies of orally administered ciprofloxacin, lomefloxacin, enoxacin, pefloxacin, and ofloxacin have indicated variation in the pharmacokinetics of some of these agents when administered with food (4, 7, 9, 10, 18, 20) . Data for ciprofloxacin suggest that administration concurrently with food containing calcium in a liquid form results in an approximately 35% decrease in the peak concentration (Cm.) and area under the curve (AUC) (13) . Similar results have been noted for norfloxacin (8) . Studies conducted after administration of single oral doses of fleroxacin have shown that food does not affect the pharmacokinetic parameters of this drug in a clinically significant * Corresponding author. Mailing address: The Mary Imogene Bassett Hospital, One Atwell Road, Cooperstown, NY 13326-1394. Phone: (607) 547-3399. Fax: (607) 547-6914. fashion (6, 11, 17, 21) . However, no studies have been conducted after administration of multiple-dose regimens. Multiple-dose regimens mimic the manner in which antibiotics are used in the clinical setting more closely than single doses do. In addition, shorter sampling periods are needed, thus decreasing costs associated with specimen collection and assay.
The purpose of the present study was to determine the influence of a fat-and calcium-rich breakfast on pharmacokinetics of single and multiple doses of fleroxacin. The calcium source for this study was a liquid source (whole milk) which has been shown to cause a clinically and statistically significant reduction in the absorption of oral ciprofloxacin (13) . On day 1 of the study, subjects were randomly assigned to the order in which they would receive four dosing regimens of fleroxacin. After the subjects received one of the four designated phases, they were allowed a minimum 7-day washout period and then crossed over to receive one of the other phases. Each subject participated in all four phases.
MATERUILS AND METHODS
Fleroxacin dosing regimens were as follows: (i) fleroxacin (400 mg) once daily for 3 days (multiple dose) in the fasted state, (ii) fleroxacin (400 mg) once daily for 3 days (multiple dose) in the fed state immediately following a standard breakfast, (iii) fleroxacin (400 mg) single dose in the fasted state, and (iv) fleroxacin (400 mg) single dose in the fed state immediately following a standard breakfast. All doses were given between 0700 and 0900 h. All subjects had no food or liquid for at least 12 h before the fleroxacin dose.
The standard breakfast used during the fed phases of the study consisted of 240 ml of whole milk, two eggs scrambled in three teaspoonsful of margarine, two strips of bacon, one slice of white toast with one teaspoonful margarine and one tablespoonful of jelly, and 120 ml of orange juice. This breakfast provided 770 calories total, 58% fat (50 g), 29% carbohydrate (55 g), 13% protein (25 g), and 393 m of calcium in a liquid form. Subjects consumed the breakfast over a 15-min period, and at the completion of the breakfast the fleroxacin dose was immediately administered with 120 ml of water. The drug was given (by one of the investigators, L.S.) on each of the three study days following the standard breakfast. Volunteers did not eat for 4 h after the breakfast and/or the fleroxacin dose. No alcohol was consumed for 3 days before and during each study phase.
During the multiple-dose phases, blood samples for fleroxacin assay were collected before the first dose (baseline), before the third dose, and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, and 24 h after fleroxacin administration. During the single-dose study phases, blood samples were collected as above and additionally at 36, 48, 60, and 72 h after fleroxacin administration.
Baseline urine samples (30 ml) were collected before the first dose during each study period. During the study phases, following bladder emptying, a 24-h urine sample was collected for fleroxacin analysis in the multiple-dose phases and a 72-h urine sample was collected in 24-h aliquots for fleroxacin determination in the single-dose phases. Baseline blood and urine samples were used as blank samples to ensure lack of assay interference for each subject.
Serum and urine fleroxacin concentrations were determined by using a specific high-pressure liquid chromatography assay. Briefly, to 250 ,ul of serum or urine was added 20 ml of 30-,ug/ml pipemidic acid and 250 ,ul of 25% Na2SO4 (plasma) or 0.5 M phosphate buffer (pH 7.5; urine). After the tube was vortexed, 3.5 ml of chloroform was added and the tube was shaken at low speed for 10 min and centrifuged at 1,155 x g for 10 min. The top layer was then aspirated, leaving a 3-ml organic layer. To (22) . Data are expressed as mean ± standard deviation. A P value of .0.05 was considered statistically significant.
RESULTS
A total of 20 subjects, 10 men and 10 premenopausal women, were enrolled in this protocol. Seven subjects were smokers (two men, five women). The mean age of the subjects was 38.3 ± 6.5 years, and their mean weight was 74.0 ± 13.1 kg. No subject had a baseline urine or serum sample positive for fleroxacin before any study phase. Table 1 and Fig. 1 and 2 illustrate the effect of a fat-and calcium-rich breakfast on pharmacokinetic parameters of single-and multiple-dose fleroxacin administration. There were statistically significant (P c 0.05) differences between the fed and fasted phases for Cm. ( 5].I) ± 11.6** "MD-Fast, multiple-dose fasted phase; SD-Fast, single-dose fasted phase; MD-Fed, multiple-dose fed phase; SD-Fed, single-dose fed phase. "Symbols: *, P -0.05 versus corresponding fasting phase, using ANOVA; **, P -0.05 versus corresponding fasted phase, using a paired t test; (ii, P -).05 versus corresponding single-dose phase, using ANOVA; #, P ().5 versus corresponding fasting phase, using the two one-sided tests procedure, where statistical significance indicates equivalence within the range ± 20% (see text for Westlake's 90% confidence intervals for relative bioavailabilities).
' CL/F, total body clearance/relative bioavailability. d Values in this column are harmonic means.
differences (P > 0.05) between the fed and fasted phases in either single-or multiple-dose regimens. AUCs for both multiple-dose and single-dose phases were statistically different (P . 0.05), using difference testing by ANOVA. When bioequivalence testing was performed, however, the mean AUCs in the fed and fasted phases for both single-and multiple-dose regimens were (13) . This inhibitory effect on the absorption of quinolones when administered with meals containing liquidcalcium sources has also been shown for norfloxacin (13) . Limited data on ofloxacin (12) 
